These differences, however, did not reach statistical significance and the authors concluded that in patients with mild-to-moderately impaired hepatic function there is no need to adjust the dose.
← all excerpts
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
1
—
—